1. Tony Simon MRCVS Director European Scientific Affairs, Zoetis
Animal Health – the⁁ issues: - and what it will mean for the Animal Health Industry
future
Tony Simon MRCVS
Director European Scientific Affairs, Zoetis

2. Here and now…
Not currently a significant therapeutic crisis in veterinary medicine. Challenges exist with:
Methicillin-resistant Staph. pseudintermedius (MRSP) in dogs
MDR Brachyspira hyodysenteriae (swine dystentry) in pigs
MDR bovine respiratory disease pathogens (in the US)
Interesting to speculate why
Biosecurity?
Vaccine use?
Vets have access to, and use, a wide range of treatment options (less pressure on any particular class)?
Culling of ‘non-responders’ or likely non-responders (on welfare and economic grounds)? ??

3. Here and now… what antibiotics are actually used in veterinary medicine?
15 October 2014
EMA/333921/2014
Veterinary Medicines Division
Majority of use in tetracyclines (tet, oxytet, chortet, doxy), penicillins (pen, amp, amoxy, amoxy-clav, clox) and sulfonamides
In addition, low overall use of 3rd/4th generation cephalosporins (0.2%) and fluoroquinolones (1.7%)
[Note: growth promoting use banned in the EU since 2006]

4. Prediction is very difficult, especially if it's about the future
Prediction is very difficult, especially if it's about the future [Niels Bohr]
Zoonotics (Campylobacter, Salmonella)
Solution: break the cycle of transmission from animal sources to humans
Addresses AMR and human burden of disease
EG in England& Wales <0.6% of human non-typhoidal Salmonella enterica CTX-R
Livestock-associated MRSA (ST 398)?
mecC MRSA?
Animal Pathogens
Brachyspira: needs a pig orientated solution
MRSP: topical therapy, need for anti-infective / other approaches
MDR bovine pneumonia pathogens (in US)
Animal pathogenic ESBLs: not a major issue, yet, but… ??
‘Humanoses’ (reverse zoonoses)
MRSA in dogs, horses

5. Quo Vadis?
‘Society’ (and therefore politics) is asking for mutually exclusive (or very difficult) food outcomes:
CHEAP Availability
The future…
There will be a need for new veterinary antibiotics
However very, very few active AH antibiotic lead-seeking / discovery programmes
Therapeutic alternatives to antibiotics may be challenging…
In addition, clear opportunities exist with ‘classic’ prevention / holistic strategies (e.g. vaccines, diagnostics etc)
Challenges for the Animal Health antibiotic R&D and business models:
Human Health FIRST
Increasing genericisation
What target profile? Narrow vs broad spectrum vs ‘veterinary’ spectrum?
What value drivers? Short acting, long acting? Therapy, metaphylaxis?
What will the future market (10-15 years time) look like (market size, approvability, restrictions in use)?
What lessons can should must be learnt from Human Health?
‘Antibiotic-free’, “hormone-free (!)”,
SAFE
‘free-range’, ‘low food miles’ etc etc